World Trade Organization (WTO) members remain divided on the extension of intellectual property flexibility for COVID-19 diagnostics and therapeutics under paragraph eight of the MC12 TRIPS Agreement, reached on June 17 last year, and substantive progress on the moratorium on e-commerce duties continues to elude delegates.
This item is available in full to subscribers.
To continue reading, you will need to either log in to your subscriber account, below, or purchase a new subscription.
If you are a current subscriber, and had an account on our previous site, you already have an account. If you have not yet logged into our new site, click here to reset your password.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
